Left Ventricular Dysfunction Clinical Trial
Official title:
Preoperative Optimization of the High-Risk Patient Undergoing Hip Fracture Surgery
Elderly patients undergoing surgery for proximal hip fracture have a high risk of morbidity and mortality (M&M) postoperatively. Several studies including some from the investigators department have shown that there is a high risk of cardiovascular complications in this group of patients and 3-month mortality is 15-20%. One of the causes of this high M&M is the high incidence of cardiac failure associated with an increased NT-proBNP in this group of patients. The aim of the present study is to evaluate whether optimization of preoperative cardiac function can reduce cardiac M&M postoperatively. Following verbal consent, patients with an increased NT-proBNP would be randomized to goal-directed preoperative optimization or standard management according to current hospital routines. Following optimization, the patients would be transferred to the operating rooms and subsequent management including perioperative patient management would be left to the discretion of a specialist anesthesiologist who is directly involved in patient care. Postoperatively, Troponin T and NT-proBNP would be measured in all patients according to the study protocol. In addition, major adverse cardiac events would be documented and follow-up would be done by after 30 days and 3 months postoperatively.
This is a prospective, open, randomized, multi-center study. Primary screening of patients
would take place in the Emergency room or Orthopedic ward according to the inclusion and
exclusion criteria (see below). All patients (>= 65 yr) with a proximal hip fracture would
be required to provide either written or verbal informed consent prior to being included in
the study. Subsequently, NT-proBNP would be taken and if this is above the recommended
levels suggesting cardiac failure (> 900 ng/l in patients 65-75 yrs old, and >1800 ng/l in
patients > 75 yrs), the patients may be included into the study. Included patients would
then be randomized into two groups: Standard management according to existing hospital
routines and Optimized Management Patients with a normal NT-proBNP would be listed but would
not be included in the study. Patients with proximal femur fracture who are > 65 yrs old and
have an increased NT-proBNP and who have given informed consent would be randomized to
either Standard Management or Optimized Management. The former group would be managed
according to the hospital routines and cared for by a Specialist Anaesthesiologist and
Orthopaedic surgeon preoperatively.
Group O= Optimization Patients who are randomized to the Optimization group would be
transferred to a Holding Area, which is close to the Operating Rooms 4-6 hours prior to
planned surgery. The main aim of optimization is to achieve a normal oxygen delivery to the
tissues preoperatively i.e. DO2: 500-600ml/min/m2. Optimized management means that patients
first have an Echocardiography to evaluate myocardial function. Subsequently, an arterial
line is inserted and optimization achieved by using this arterial line connected to a
Flo-track system (Vigileo, Edwards). The system uses pulse wave analysis to assess several
parameters including: stroke volume index (SVI), cardiac index (CI), systemic vascular
resistance index (SVRI), as well as oxygen delivery (DO2).The main aim of goal-directed
therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.• Hb
would be optimized to > 90 g/l
- SaO2 > 96%
- Stroke volume index (SVI) > 30
- Heart rate should ideally be < 80
Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of
100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to
use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goa
The study would be done in three hospitals: University Hospital, Linköping, University
Hospital, Örebro and Jönköping Hospital. A total of 200 patients (100 in each group) would
be included. It is expected that the study would be ongoing during a period of two years.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05529654 -
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
|
N/A | |
Recruiting |
NCT04671966 -
Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT05188222 -
Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery
|
Phase 4 | |
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT01076920 -
Mesenchymal Stem Cells and Myocardial Ischemia
|
Phase 1/Phase 2 | |
Completed |
NCT01128790 -
Pilot Study of Remote Ischemic Preconditioning in Heart Failure
|
N/A | |
Completed |
NCT04942353 -
Effects of Home-based Exercise Rehabilitation on Healthcare Utilization in HeartMate 3 Patients
|
N/A | |
Recruiting |
NCT05769036 -
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
|
N/A | |
Completed |
NCT03232736 -
InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
|
||
Recruiting |
NCT04694092 -
Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation
|
N/A | |
Completed |
NCT01609738 -
Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum
|
Phase 1/Phase 2 | |
Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
Completed |
NCT00551681 -
Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure
|
N/A | |
Not yet recruiting |
NCT04103008 -
Left Ventricular Function After Primary Percutaneous Coronary Intervention: Role of Speckle Echocardiography
|
||
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|
||
Recruiting |
NCT05860504 -
Acute Cardiac Dysfunction in Critical Illnes
|
||
Completed |
NCT03787810 -
Left Ventricular Dysfunction in Critically Ill Patients
|
||
Completed |
NCT01093001 -
Tricuspid Regurgitation Study
|
Phase 4 | |
Active, not recruiting |
NCT00461734 -
PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
|
N/A | |
Recruiting |
NCT04752293 -
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
|